<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1656095-B1" country="EP" doc-number="1656095" kind="B1" date="20140101" family-id="34272488" file-reference-id="316847" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146553835" ucid="EP-1656095-B1"><document-id><country>EP</country><doc-number>1656095</doc-number><kind>B1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-04801985-A" is-representative="NO"><document-id mxw-id="PAPP154827758" load-source="docdb" format="epo"><country>EP</country><doc-number>04801985</doc-number><kind>A</kind><date>20040817</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140447503" ucid="US-2004026603-W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2004026603</doc-number><kind>W</kind><date>20040817</date></document-id></priority-claim><priority-claim mxw-id="PPC140447550" ucid="US-49620703-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>49620703</doc-number><kind>P</kind><date>20030818</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130816</date></intention-to-grant-date><search-report-dispatch-date><date>20071031</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988099862" load-source="ipcr">C07C 311/32        20060101ALI20071022BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988101670" load-source="ipcr">A61K               20060101S I20070224RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988109670" load-source="ipcr">C07C 239/04        20060101ALI20071022BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988111071" load-source="ipcr">A61K  31/195       20060101A I20051110RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988112830" load-source="ipcr">A61K  31/69        20060101A I20051110RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988113527" load-source="ipcr">C07C 229/00        20060101AFI20061027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988114568" load-source="ipcr">A01N  41/08        20060101A I20080531RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988117293" load-source="ipcr">A61K  31/66        20060101A I20051110RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988120684" load-source="ipcr">C07C 309/14        20060101ALI20071022BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988125851" load-source="ipcr">A01N  59/00        20060101A I20080531RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988127952" load-source="ipcr">C07C 309/18        20060101ALI20071022BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988134241" load-source="ipcr">A61K  31/13        20060101A I20051110RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988100254" load-source="docdb" scheme="CPC">A01N  59/00        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988103019" load-source="docdb" scheme="CPC">A01N  41/08        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988115632" load-source="docdb" scheme="CPC">C07C 309/14        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988118038" load-source="docdb" scheme="CPC">C07C 239/04        20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132193989" lang="DE" load-source="patent-office">N,N-DIHALOGENIERTE AMINOSÄUREN UND DERIVATE</invention-title><invention-title mxw-id="PT132193990" lang="EN" load-source="patent-office">N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES</invention-title><invention-title mxw-id="PT132193991" lang="FR" load-source="patent-office">ACIDES N,N-DIHALOGENES ET DERIVES DE CES DERNIERS</invention-title></technical-data><related-documents><relation type="division-into"><child-doc ucid="EP-13189882.7"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13189882.7</doc-number><date>20131023</date></document-id></child-doc><parent-doc ucid="EP-04801985-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>04801985</doc-number><kind>A</kind><date>20040817</date></document-id><parent-grant-document ucid="EP-1656095-B1"><document-id><country>EP</country><doc-number>1656095</doc-number><kind>B1</kind><date>20140101</date></document-id></parent-grant-document></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR918157217" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>NOVABAY PHARMACEUTICALS INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918164990" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>NOVABAY PHARMACEUTICALS, INC.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918169289" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BASSIRI MANSOUR</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918144252" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BASSIRI, MANSOUR</last-name></addressbook></inventor><inventor mxw-id="PPAR918998117" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BASSIRI, MANSOUR</last-name><address><street>2128 Bueno Drive 23</street><city>Davis, CA 95616</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918163972" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>NAJAFI RAMIN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918145770" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>NAJAFI, RAMIN</last-name></addressbook></inventor><inventor mxw-id="PPAR918998118" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>NAJAFI, RAMIN</last-name><address><street>310 Marin Oaks Drive</street><city>Novato, CA 94949</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918158949" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>WANG LU</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918139122" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>WANG, LU</last-name></addressbook></inventor><inventor mxw-id="PPAR918998116" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>WANG, LU</last-name><address><street>5980 Horton Street, Suite 550</street><city>Emeryville, CA 94608</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918137617" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>YANG JANE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918136745" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>YANG, JANE</last-name></addressbook></inventor><inventor mxw-id="PPAR918998119" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>YANG, JANE</last-name><address><street>5980 Horton Street, Suite 550</street><city>Emeryville, CA 94608</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR918998121" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>NovaBay Pharmaceuticals, Inc.</last-name><iid>100997556</iid><address><street>5980 Horton Street Suite 550</street><city>Emeryville CA 94608</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR918998120" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>HOFFMANN EITLE</last-name><iid>100061036</iid><address><street>Patent- und Rechtsanwälte Arabellastrasse 4</street><city>81925 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2004026603-W"><document-id><country>US</country><doc-number>2004026603</doc-number><kind>W</kind><date>20040817</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2005020896-A2"><document-id><country>WO</country><doc-number>2005020896</doc-number><kind>A2</kind><date>20050310</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548885588" load-source="docdb">AT</country><country mxw-id="DS548987018" load-source="docdb">BE</country><country mxw-id="DS548983069" load-source="docdb">BG</country><country mxw-id="DS548980071" load-source="docdb">CH</country><country mxw-id="DS548830230" load-source="docdb">CY</country><country mxw-id="DS548885589" load-source="docdb">CZ</country><country mxw-id="DS548987019" load-source="docdb">DE</country><country mxw-id="DS548830231" load-source="docdb">DK</country><country mxw-id="DS548830232" load-source="docdb">EE</country><country mxw-id="DS548868178" load-source="docdb">ES</country><country mxw-id="DS548983070" load-source="docdb">FI</country><country mxw-id="DS548980072" load-source="docdb">FR</country><country mxw-id="DS548987020" load-source="docdb">GB</country><country mxw-id="DS548830233" load-source="docdb">GR</country><country mxw-id="DS548885590" load-source="docdb">HU</country><country mxw-id="DS548980709" load-source="docdb">IE</country><country mxw-id="DS548980073" load-source="docdb">IT</country><country mxw-id="DS548830234" load-source="docdb">LI</country><country mxw-id="DS548990591" load-source="docdb">LU</country><country mxw-id="DS548983071" load-source="docdb">MC</country><country mxw-id="DS548980710" load-source="docdb">NL</country><country mxw-id="DS548980711" load-source="docdb">PL</country><country mxw-id="DS548983072" load-source="docdb">PT</country><country mxw-id="DS548885591" load-source="docdb">RO</country><country mxw-id="DS548980712" load-source="docdb">SE</country><country mxw-id="DS548980074" load-source="docdb">SI</country><country mxw-id="DS548868179" load-source="docdb">SK</country><country mxw-id="DS548990592" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63957455" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">1. <u>FIELD OF THE INVENTION</u></heading><p id="p0001" num="0001">The present invention relates to bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions on the basis of amino acids and their derivatives that have the ability to release halogen and to new uses of these compositions in therapy.</p><p id="p0002" num="0002">This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds. More specifically, these halogenated amino acids and their derivatives are also referred to herein as amino acids.</p><p id="p0003" num="0003">The starting materials may be used in form of their esters or salts. The term halogen as used herein includes chloro, bromo and iodo.</p><p id="p0004" num="0004">The starting materials for the NN-dihalo amino acids are generally known compounds or may be prepared by known methods. These materials are described in <nplcit id="ncit0001" npl-type="s"><text>Tetrahedron: Asymmetry 1997, 8 (13</text></nplcit>), <nplcit id="ncit0002" npl-type="s"><text>FEMS Microbiol. Lett., 70, 23-28 (1990</text></nplcit>), <nplcit id="ncit0003" npl-type="s"><text>Synth.<!-- EPO <DP n="2"> --> Commun. 2725-2731 (1994</text></nplcit>), <nplcit id="ncit0004" npl-type="s"><text>FEMS Microbiol. Lett. 108, 225-230 (1993</text></nplcit>), <nplcit id="ncit0005" npl-type="s"><text>Neurosci. Lett. 21: 77-92 (1981</text></nplcit>), <nplcit id="ncit0006" npl-type="s"><text>Br. J. Pharmacol. 75, 65</text></nplcit>, and for example, in<nplcit id="ncit0007" npl-type="s" url="www.nobel.se/chemistry/laureates/2001/noyori-lecture.pd.f"><text> Prof. R. Noyori Nobel Lecture 'Asymmetric Catalysis: Science and Opportunities' dated December 8,2001 (www.nobel.se/chemistry/laureates/2001/noyori-lecture.pd.f</text></nplcit>).</p><p id="p0005" num="0005">A number of the N, N-dihalogenated amino acids are known. With respect to these amino acids and their derivatives, we provide new compositions with bactericidal, antibacterial, anti-infective, antimicrobial, antifungal and antiviral properties.</p><p id="p0006" num="0006">The invention also relates to a number of new N, N-dihalogenated amino acids and their derivates with bactericidal, antibacterial, anti-infective, sporicidal, antimicrobial, antifungal, and antiviral properties.</p><heading id="h0002">2. <u>BACKGROUND OF THE INVENTION</u></heading><p id="p0007" num="0007">A body's immune cells, the neutrophils and macrophages that are known for their abilities to clear infection can generate reactive oxygen metabolites that destroy microorganisms and normal or neoplastic (cancerous) cells and modulate inflammatory responses.</p><p id="p0008" num="0008">Neutrophils can be activated as a response to inflammatory stimuli, bacterial infection and / or other membrane changes. As a result, they produce super oxide radicals such as: HOO<sup>.</sup>, O<sub>2</sub><sup>.</sup>, and OH<sup>.</sup>. Chloride ion (Cl<sup>-</sup>) at physiological concentrations of 100-150 mM is oxidized by H<sub>2</sub>O<sub>2</sub>, which is catalyzed by myeloperoxidase (an enzyme within the neutrophils) to form hypochlorous acid (HOCl) and HCl.</p><p id="p0009" num="0009">Physiological generation of HOCl is tightly regulated through feedback inhibition by an intricate network of biochemical signals. HOCl is generated at a concentration of 2 x 10<sup>-7</sup> M per 10<sup>6</sup> activated neutrophils. This quantity of HOCl is estimated to kill approximately 150 x 10<sup>6</sup> E. coli bacteria. Once HOCl is produced, it degrades rapidly by reacting with multiple oxidizable substrates within the complex cell system. Thus, the concentrations of reactive oxygen-metabolites are expected to fall to undetectable levels within hours. However, it has been demonstrated that neutrophils can use their HOCl to generate large quantities of a rather long-lived oxidants, such as N-chloramines. These long-lived oxidants are generated as monochloramines of taurine (NCT, or N-chlorotaurine) and dichloramines of taurine (NNDCT, or N,N-dichlorotaurine) depending on the pH of the cellular environment. These oxidants are powerful antimicrobials and play key roles within the defense system as well as modulating the cytokines and growth factors in the host body.<!-- EPO <DP n="3"> --></p><heading id="h0003">3. <u>DESCRIPTION OF RELATED ART</u></heading><p id="p0010" num="0010">German Patent Application <patcit id="pcit0001" dnum="DE4041703"><text>4041703 W. Gottardi</text></patcit> describes alkali metal salts of N-chlorotaurine. The application mentions that it has not been possible to isolate N-chlorotaurine as a pure substance but only in the form of a diluted solution when it is prepared <i>in situ.</i> Later work established that N-chlorotaurine could be prepared as described below. The German patent application also describes the preparation of pure alkali metal salts of N-chlorotaurine in crystalline form. It also discloses the use of these salts as disinfectants and bactericides in medicinal applications to humans. The German application describes the preparations of the alkali metal salts by the reaction of taurine with an alkali metal chloramide, such as N-chlorobenzene sulfonamide sodium (Chloramine-B) or N-chloro-4-methyl-benzene sulfonamide sodium (Chloramine-T). Chloramine-B and Chloramine-T are listed in the <nplcit id="ncit0008" npl-type="b"><text>Merck Index, Thirteenth Edition, 2001, Entries 2084 and 2085 on page 356</text></nplcit>.</p><p id="p0011" num="0011"><patcit id="pcit0002" dnum="WO0222118WA"><text>WO0222118 W. Gottardi et al.</text></patcit> describe N-chlorotaurine, in particular in the form of its sodium salt as useful for the treatment of fungal infections, such as acute or chronic <i>Rhinosinusitis</i> or other fungal infections such as <i>Otitis, Dermatitis, Bronchititis,</i> diverse forms of pneumonia, such as <i>Pneumocystis carinii,</i> the fungal infections of sex organs, such as <i>Colpitis, Endometritis, Balnitis,</i> fungal infections of the gastrointestinal tract, such as <i>Stomatitis, Oesophagitis, Enteritis,</i> or fungal infections of the urethra, such as <i>Pyelonephrititis, Ureteritis, Cystitis,</i> or <i>Urethritis.</i></p><p id="p0012" num="0012">Recently Gelder <i>et al.</i> have synthesized and isolated N,N-dichlorotaurine as a powder (<nplcit id="ncit0009" npl-type="s"><text>Gelder, N. M.; Bowers, R. Synthesis and characterization of N,N-dichlorinated amino acids: Taurine, Homotaurine, GABA and L-Leucine J. Neurochemical Research. 2001; 26:575-578</text></nplcit>). N-chlorotaurine (NCT) and N,N-dichlorotaurine (NNDCT) can be identified by their UV spectra. NNDCT has a maximum absorbance at 302 mM with a molar absorptivity of 332.9 M<sup>-1</sup>cm<sup>-1</sup>. These values are from <nplcit id="ncit0010" npl-type="s"><text>Gottardi, W.; Nagl, M. Arch. Pharm. Med. Chem. 2002, 9, 411-421</text></nplcit>. NCT has a maximum absorbance at 252 nm with a molar absorptivity of 415 M<sup>-1</sup>cm<sup>-1</sup>.</p><p id="p0013" num="0013"><nplcit id="ncit0011" npl-type="s"><text>Juan M. Antelo et al., J. Chem. Soc., Perkin Trans. 2, 2000, 2109-2114</text></nplcit> described the general acid-base catalysis in the reversible disproportionation reaction of N-chlorotaurine. The authors also describe the preparation of solutions of N,N-dichlorotaurine by disproportionation of N-chlorotaurine at pH 2-2.5 and the stability of<!-- EPO <DP n="4"> --> N,N-dichlorotaurine at pH = 1.88. The loss ofN, N-dichlorotaurine was less than 5% after 5 hours.</p><p id="p0014" num="0014"><patcit id="pcit0003" dnum="US4386103A"><text>US 4,386,103</text></patcit> relates to dichloroamino acid derivatives that are useful as germicidal and fungicidal agents. The compounds described in <patcit id="pcit0004" dnum="US4386103A"><text>US 4,386,103</text></patcit> are amino acids and derivatives thereof all having a carboxylic acid group. The document does not disclose amino acids or amino acid derivatives having a sulfonic acid group.</p><p id="p0015" num="0015"><patcit id="pcit0005" dnum="WO9830116A"><text>WO 98/30116</text></patcit> relates to the food preservation by extended hydraulic pressure. In specific examples of the document, monochlorotaurine and dichlorotaurine are used as preservatives.</p><heading id="h0004">SUMMARY OF THE INVENTION</heading><p id="p0016" num="0016">In its broadest aspect, the present invention provides a composition with bactericidal, antibacterial, anti-infective, antimicrobial, disinfectant, antifungal, sporicidal and antiviral activity comprising an N,N-dihalo-amino acid selected from the group consisting of N,N-dichloro-2,2-dimethyltaurine, N,N-dichloro-1,1,2,2-tetramethyltaurine, N,N-dibromo-2,2-dimethyltaurine, N,N-dibromo-1,1,2,2-tetramethyltaurine, N,N-dichloro-3,3-dimethylhomotaurine, or a derivative thereof; said derivative being selected from the group consisting of pharmaceutically acceptable salts and esters with C<sub>1</sub>-C<sub>6</sub> alkanols.</p><p id="p0017" num="0017">A preferred composition of the invention comprises has a concentration of the N,N-dihaloamino acid between 0.1 to 50mM and a pH range between 2 to 7, or 3.0 to 6.0, or 3.0 to 5.0, or 3.5.<!-- EPO <DP n="5"> --></p><p id="p0018" num="0018">The pharmaceutically acceptable salts include salts with pharmaceutically acceptable cations. The salts of the N,N-dihaloamino acid includes salts of bases with the -SO<sub>3</sub>H group. Pharmaceutically<!-- EPO <DP n="6"> --> acceptable salts also include ammonium, alkali metal, magnesium, or calcium salts and any organic amine salts. Alkali metal salts, Mg, Ca and A1 salts are of interest. The alkali metal salts are of particular interest, particularly lithium, sodium, or potassium salts.</p><p id="p0019" num="0019">Examples of acid addition salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids, and the like. Pharmaceutically acceptable salts include, but are not limited to, hydrohalides, sulfates, methosulfates, methanesulfates, toluenesulfonates, nitrates, phosphates, maleates, acetates, lactates and the like.</p><p id="p0020" num="0020">Lists of suitable salts are found in <nplcit id="ncit0012" npl-type="b"><text>Remington's Pharmaceutical Sciences, 17th ed, Mack Publishing Company, Easton, Pa., 1985, p. 1418</text></nplcit> or <nplcit id="ncit0013" npl-type="b"><text>The Merck Index, Thirteenth Edition, 2001, Published by Merck Research Laboratories Division of Merck &amp; Co., Inc. on pages MISC-22 and MISC-23</text></nplcit>, the disclosures of which are hereby incorporated by reference in their entirety.<!-- EPO <DP n="7"> --></p><p id="p0021" num="0021">The term "composition" as used herein, refers to various forms of the compounds or compositions of the present invention, including solids such as powders, mixtures of powders and the like, emulsions, suspensions as well as solutions.</p><p id="p0022" num="0022">The compositions and their uses include new N,N-dihaloamino acids or their derivatives. The compositions may be maintained in acidic form, that is at a pH below 7, for example 6.8, that is at a pH between 2 to 7, that is at a pH range between 2.0 to 6.8, 2.5 to 6.5, 2.5 to 6.0, or 2.5 to 5.0, or 3.0 to 5.0, or at a pH of 3.5. Under different circumstances the pH may be kept below 5, that is, at a pH range of 3 to 4.5, or 3.5 to 4.5, or at a pH 3.5. The key is that the pH of the composition is acidic. The selection of the pH will depend on many factors, including the specific use of the N,N-dihaloamino acid (whether <i>in vitro</i> or in <i>vivo</i>), the type of the infection treated (for example, whether the infection is caused by bacteria, yeast, fungi or viruses), the site of the infection (for example, whether it is an infection of the eye, the larynx or the urethra or any target tissue or organ), the severity of the infection, the sensitivity of the patient, etc.</p><p id="p0023" num="0023">In another aspect the composition, the solutions of the invention contain N,N-dihaloamino acids in the concentration range of 0.1 to 100 millimolar (mM).</p><p id="p0024" num="0024">In a further aspect the composition will be isotonic and physiologically balanced.</p><p id="p0025" num="0025">The N,N-dihaloamino acids differ significantly from HOCl because they maintain an oxidizing potential with significant bactericidal activities, and yet they are less toxic than HOCl. N,N-dihaloamino acids are also stable enough to diffuse some distance before oxidizing susceptible target molecules. The low molecular weight N,N-dihaloamino acids of the present invention with n=0 or an integer up to 5 are more hydrophilic molecules.<!-- EPO <DP n="8"> --></p><p id="p0026" num="0026">Surprisingly, it has been found that, while the N,N-dihalo-amino acids of the invention have strong bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral, they have low cytotoxicity.</p><p id="p0027" num="0027">In a further aspect the compositions of the invention are stabilized to meet the requirement of being useable as compositions for the treatment or prevention of bacterial, microbial, spore, fungal and viral infections or contaminations.</p><p id="p0028" num="0028">In another aspect the stabilization of the composition is provided by storing the compositions in a receptacle that will ensure sufficient stability to control bacterial, microbial, spore, fungal and viral infections or contaminations.</p><p id="p0029" num="0029">Derivatives of the compounds include pharmaceutically acceptable salts, and esters with lower alkanols. The term "lower" in this respect includes residues with 1 to 6, preferably 1 to 4 carbon atoms.<!-- EPO <DP n="9"> --></p><p id="p0030" num="0030">The preferred derivatives are pharmaceutically acceptable salts.</p><p id="p0031" num="0031">In another aspect, the above-described compositions include the following compounds or a derivative thereof; said derivative being selected from the group consisting of pharmaceutically acceptable salts and esters with lower alkanols:
<ul><li>N,N-dichloro-2,2-dimethyltaurine;</li><li>N,N-dichloro-1,1,2,2-tetramethyltaurine;</li><li>N,N-dibromo-2,2-dimethyltaurine;</li><li>N,N-dibromo-1,1,2,2-tetramethyltaurine;<!-- EPO <DP n="10"> --></li><li>N,N-dichloro-3,3-dimethylhomotaurine;</li></ul>
or a pharmaceutically acceptable salt or ester with C<sub>1</sub>-C<sub>6</sub> alkanols.</p><p id="p0032" num="0032">In another aspect, the compositions of the invention further comprises a pharmaceutically acceptable carrier.<!-- EPO <DP n="11"> --></p><p id="p0033" num="0033">Again, all the features, characteristics and ranges described for the invention, in any aspect, whether described as of interest or as particular or not, may be combined with each other.</p><heading id="h0005"><u>Processes for the Preparation of N,N-Dihalo-amino Acids and Derivatives</u></heading><p id="p0034" num="0034">The N,N-dihaloamino acids and derivatives are prepared by the reaction of the amino acid or a derivative thereof from which the halogenated amino acids are produced with a halogen source under reaction conditions which lead to the replacement of two hydrogen atoms at the -amino group of the amino acid with two halogen atoms, that is chloro, or bromo atoms. These processes are known to chemists skilled in the art.</p><p id="p0035" num="0035">In one aspect of the invention, the amino acids that are used as starting materials include taurine and, homotaurine. In another aspect, these starting materials may be used in form of their esters or salts. All these starting materials are either well-known, commercially available, or may be prepared by well-known methods of preparation. A number of the starting materials are commercially available, for example from Sigma-Aldrich.</p><p id="p0036" num="0036">The following non-exclusive halogen sources may be used to produce the N,N-dihaloamino acids and their derivatives: HOCl or its salts (for example, NaOCI or KOCl), N-haloarylsulfonamide salts, wherein the aryl group contains from 6 to 15<!-- EPO <DP n="12"> --> carbon atoms with 1 or 2 aromatic rings, 6 to 10, or 6 to 8, carbon atoms and one aromatic ring, such as N-halobenzene-sulfonamide or N-halo-4-alkylbenzenesulfonamide, wherein the alkyl group is lower alkyl from 1 to 4 carbons, methyl or ethyl. The N-halobenzena-sulfonamides or N-halo-4-alkylbenzenesulfonamides are often used in form of their salts, for example, alkali salts, for example, their sodium or potassium salts. The most frequently used reagents will be N-chlorobenzenesulfonamide and N-chloro-4-methyl-benzenesulfonamide in form of their sodium salts, because they are readily commercially available. Other non-limiting halogen releasing agents or sources may be HClO<sub>2</sub>, N-chloro-succinimide or N-bromosuccinimide, Cl<sub>2</sub>, Br<sub>2</sub>, and chlorinating agents, such as those used in swimming pools, or combinations of the agents.</p><p id="p0037" num="0037">Other amino acid starting materials include 2,2-dimethylhypotaurine, 1,1,2,2-tetramethyl-hypotaurine, 2,2-dimethyltaurine, 1,1,2,2-tetramethyltaurine, and 3,3-dimethylhomotaurine.</p><p id="p0038" num="0038">If one molecule of the halogen source releases one halogen, obviously for each starting amine of the amino acid or derivative molecule at least two molecules of the halogen source will be used. More details of the preparation of N,N-dihaloamino acids and their derivatives are set forth in the examples.<!-- EPO <DP n="13"> --></p><p id="p0039" num="0039">Compounds according to the present invention can also include their individual stereoisomers (enantiomers and diastereoisomers) as well as the racemic mixtures of the compound. The individual isomers, such as the pure R, S, RR, SS, RS, SR, etc. may be prepared by treating the isomeric mixture with an optically active resolving agent to form a pair of diastereoisomeric compounds. The diastereoisomeric compounds may be separated and the optically pure enantiomer or diastereomer may be isolated using procedures well known in the art. Because diastereomers have distinct physical properties (such as the melting points, boiling points, solubilities, reactivity, etc.), they can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation or resolution techniques based upon differences in solubility. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in <nplcit id="ncit0014" npl-type="b"><text>Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley &amp; Sons, Inc. (1981</text></nplcit>) and references cited therein.</p><p id="p0040" num="0040">The amino acid starting material is dissolved in a lower alkanol (for example, methanol or ethanol) and made acidic. To this solution an aqueous NaOCl solution is added. The reaction results in the chlorination of the amino group and the precipitation of sodium chloride. The solvent is evaporated at low temperatures, for example, below 30 °C and a residue is obtained. The residue is taken up in a solvent and the N,N-dihaloamino acid isolated by extraction with a solvent not miscible with the aqueous<!-- EPO <DP n="14"> --> lower alkanol phase. Similarly the N,N-dihalo-amino acid may be prepared by reacting the amino acid starting material with HOCl.</p><p id="p0041" num="0041">Accordingly, the bromo analogs may also be prepared with NaOBr as the halogenating agent.</p><p id="p0042" num="0042">According to <nplcit id="ncit0015" npl-type="s"><text>J Marcinkiewicz et al 2000 (J of Inflammatory Research 49, 280-289</text></nplcit>) NNDCT (N,N-dichlorotaurine) may be synthesized in solution by reacting HOCl with taurine at pH 5. NNDCT also can be generated in the oxidation of Bunte salt (H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>S-SO<sub>3</sub>H) (<nplcit id="ncit0016" npl-type="s"><text>Chinake et al. Oxyhalogen-sulfur chemistry: kinetics and mechanism of the oxidation of a Bunte salt 2-aminoethanethiolsulfuric acid by chlorite. Phys. Chem. Chem. Phys. 2001; 3:4957-4964</text></nplcit>) and hypotaurine (H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>H) by chlorite (ClO<sub>2</sub><sup>-</sup>) (<nplcit id="ncit0017" npl-type="s"><text>Martincigh, B. S.; Mundoma, C.; Simoyi, R. H.; Antioxidant chemistry: Hypotaurine-taurine oxidation by chlorite. J. Phys. Chem. A. 1998; 102:9838-9846</text></nplcit>).</p><p id="p0043" num="0043">The reactions are shown in equations 1-6: <maths id="math0001" num="(1)"><math display="block"><mtable><mtr><mtd><mn mathvariant="normal">2</mn><mspace width="1em"/><msup><msub><mi>ClO</mi><mn mathvariant="normal">2</mn></msub><mo>-</mo></msup><mo>+</mo><msub><mi mathvariant="normal">H</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>NCH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>CH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><mi mathvariant="normal">S</mi><mo>-</mo><msub><mi>SO</mi><mn mathvariant="normal">3</mn></msub><mo>⁢</mo><mi mathvariant="normal">H</mi></mtd><mtd><mo>→</mo><msub><mi>ClNHCH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>CH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>SO</mi><mn mathvariant="normal">3</mn></msub><mo>⁢</mo><mi mathvariant="normal">H</mi><mo>+</mo><msup><msub><mi>SO</mi><mn mathvariant="normal">4</mn></msub><mrow><mn mathvariant="normal">2</mn><mo>-</mo></mrow></msup><mo>+</mo><msup><mi>Cl</mi><mo>-</mo></msup><mo>+</mo><msup><mi mathvariant="normal">H</mi><mo>+</mo></msup></mtd></mtr><mtr><mtd><mi>Bunte salt</mi></mtd><mtd><mi mathvariant="normal">N</mi><mo>-</mo><mi>chlorotaurine</mi></mtd></mtr></mtable></math><img id="ib0001" file="imgb0001.tif" wi="143" he="14" img-content="math" img-format="tif"/></maths><br/>
N-chlorotaurine disproportionates to form N,N-dichlorotaurine and taurine in acidic solution: <maths id="math0002" num="(2)"><math display="block"><mtable><mtr><mtd><mn mathvariant="normal">2</mn><mo>⁢</mo><msub><mi>ClNHCH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>CH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>SO</mi><mn mathvariant="normal">3</mn></msub><mo>⁢</mo><mi mathvariant="normal">H</mi></mtd><mtd><mo>→</mo></mtd><mtd><msub><mrow><msub><mi>Cl</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><mi>NCH</mi></mrow><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>CH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>SO</mi><mn mathvariant="normal">3</mn></msub><mo>⁢</mo><mi mathvariant="normal">H</mi><mo>+</mo></mtd><mtd><msub><mrow><msub><mi>NH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><mi>CH</mi></mrow><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>CH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>SO</mi><mn mathvariant="normal">3</mn></msub><mo>⁢</mo><mi mathvariant="normal">H</mi></mtd></mtr><mtr><mtd><mspace width="1em"/></mtd><mtd><mspace width="1em"/></mtd><mtd><mi mathvariant="normal">N</mi><mo>,</mo><mi mathvariant="normal">N</mi><mo>-</mo><mi>dichlorotaurine</mi></mtd><mtd><mi>Taurine</mi></mtd></mtr></mtable></math><img id="ib0002" file="imgb0002.tif" wi="146" he="14" img-content="math" img-format="tif"/></maths> <maths id="math0003" num="(3)"><math display="block"><mtable><mtr><mtd><msup><msub><mi>ClO</mi><mn mathvariant="normal">2</mn></msub><mo>-</mo></msup></mtd><mtd><mo>+</mo><msub><mi mathvariant="normal">H</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>NCH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>CH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>SO</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><mi mathvariant="normal">H</mi><mo>+</mo><msup><mi mathvariant="normal">H</mi><mo>+</mo></msup></mtd><mtd><mo>→</mo></mtd><mtd><msub><mi mathvariant="normal">H</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>NCH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>CH</mi><mn mathvariant="normal">2</mn></msub><mo>⁢</mo><msub><mi>SO</mi><mn mathvariant="normal">3</mn></msub><mo>⁢</mo><mi mathvariant="normal">H</mi><mo>+</mo><mi>HOCl</mi></mtd></mtr><mtr><mtd><mspace width="1em"/></mtd><mtd><mi>Hypotaurine</mi></mtd><mtd><mspace width="1em"/></mtd><mtd><mi>Taurine</mi></mtd></mtr></mtable></math><img id="ib0003" file="imgb0003.tif" wi="142" he="15" img-content="math" img-format="tif"/></maths><br/>
HOCl can rapidly oxidize the remaining hypotaurine to taurine:<br/>
<br/>
        HOCl + H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>H → H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H + Cl<sup>-</sup> + H<sup>+</sup>     (4)<br/>
<br/>
or oxidize hypotaurine to N-chlorohypotaurine:<br/>
<br/>
        HOCl + H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>H → ClHNCH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>H + H<sub>2</sub>O     (5)<br/>
<br/>
</p><p id="p0044" num="0044">In highly acidic conditions, HOCl oxidizes N-chlorohypotaurine to N, N-dichlorotaurine.<br/>
<br/>
        HOCl + ClHNCH<sub>2</sub>CH<sub>2</sub>SO<sub>2</sub>H → Cl<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H + H<sub>2</sub>O + HCl     (6)<br/>
<br/>
</p><p id="p0045" num="0045">The compounds with at least one lower alkyl group attached to the carbon atom to which the amino group is attached are more stable dihalogenated amino acids.<!-- EPO <DP n="15"> --></p><p id="p0046" num="0046">These compounds may be prepared as follows:
<chemistry id="chem0001" num="0001"><img id="ib0004" file="imgb0004.tif" wi="130" he="81" img-content="chem" img-format="tif"/></chemistry></p><p id="p0047" num="0047">Pharmaceutically-acceptable salts of the compounds of the invention may be prepared by reacting the free acid or base forms of these compounds with a stoichiometric or greater amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, for example, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol. The salts of the invention may also be prepared by ion exchange, for example.</p><p id="p0048" num="0048">Salts may also be prepared by reacting the N,N-dihaloamino acids in other manners known per se including a method analogous to the method described in German Patent Application <patcit id="pcit0006" dnum="DE4041703"><text>4041703 W. Gottardi</text></patcit>.<!-- EPO <DP n="16"> --></p><p id="p0049" num="0049">The sodium salts of the N,N-dihaloamino acids may be converted into the lower alkyl esters by reacting the sodium salt with a lower dialkyl sulfate, such as dimethyl or diethyl sulfate in the presence of sodium bicarbonate.</p><heading id="h0006"><u>Methods of Use for the N,N-dihaloamino acids and Derivatives</u></heading><p id="p0050" num="0050">The N,N-dihaloamino acids and their derivatives are antimicrobial agents which kill microbes at relatively low concentrations and can be tolerated by eukaryotic cells at significantly high concentrations. This range of therapeutic activity and favorable therapeutic index is absolutely critical considering the physiological role of chloramines in the destruction of pathogens in vivo. For an antimicrobial product that is applied to tissues such as ophthalmic, skin or any other sensitive areas its safety and efficacy cannot be compromised. Thus, use of such product(s) in humans for treating infections is supported by our positive results.</p><p id="p0051" num="0051">The N,N-dihaloamino acids and their derivatives have the following potential areas of application: contact lens cleanser, bacterial inactivation, ophthalmic, general surgical preparation, surgical instrument disinfection, medical device and instrument disinfection, dental instruments disinfection and application in food sanitation including disinfection of surface areas. They are also useful in vaccine formulations (as preservative and potentially adjuvant), as compounds with viricidal effect, for the viral inactivation of both DNA and RNA classes of viruses including HIV, hepatitis A, respiratory syncytial virus, West Nile virus, HSV-1, HSV-2, SARS, influenza and para-influenza viruses, picomaviruses, and vaccinia virus (as a Model for Poxviruses). In addition, these compounds are also useful for the treatment of fungal infections, such as acute or chronic <i>Rhinosinusitis</i> or other fungal infections such as <i>Otitis, Dermatitis, Bronchititis, Pneumonia's</i> such as <i>Pneumocystis carinii,</i> the fungal infections of sex organs, such as <i>Colpitis, Endometritis, Balnitis,</i> fungal infections of the gastrointestinal tract, such as <i>Stomatitis, Oesophagitis, Enteritis,</i> or fungal infections of the urethra, such as <i>Pyelonephrititis, Ureteritis, Cystitis,</i> or <i>Urethritis.</i> Furthermore, the compositions described herein have antimicrobial activity against many other microorganisms, including <i>Escherichia coli, Listeria monocytogenes, Staphylococcus aureus,</i> methicillin-resistant <i>S. aureus</i> (MRSA), <i>Pseudomonas aeruginosa, Lactobacillus,</i> yeast, vancomycin-resistant enterococcus, molds, and spores, including spores of anthrax. In<!-- EPO <DP n="17"> --> particular, the solutions of the present invention may be useful in the treatment of several different strains of <i>Bacillus anthracis.</i> Vancomycin-resistant bacteria, MRSA, and others are easily destroyed by the compositions of the present invention.</p><p id="p0052" num="0052">The compositions of the invention can be used in a method for the treatment for the treatment of various medical conditions selected from the groups consisting of promoting wound healing, reduction of pathogens in open wounds, wound decontamination, ocular disinfection or decontamination, oral disinfection, antifungal therapy, ophthalmic, oral surgery and dentistry, otology applications, reduction of pathogens in pulmonary infections, reduction of pathogens in bums, lavage, reduction of infectious load in organs for transplantation, reduction of bacterial load in autologous or artificial tissue transplantation, oral disinfection antifungal therapy, treatment of biofilm for cystic fibrosis or other diseases that produces biofilms, treatment of viral infections, treatment of skin diseases, and tissue repair and regeneration, which method comprises using the solution of the invention by applying the solution to the site where treatment is required.</p><p id="p0053" num="0053">The dosage for use on chronic wounds of an approximate size of 25 square cm might be in the range of 30 ml of solution containing 2 to 200 mg of active ingredient where the active ingredient is NNDCT applied one to ten times per day. In certain instances the composition may contain 0.1 to 100 mM of active ingredient. Dosages in other applications would be adjusted to the surface area depending on where the antimicrobial activity is required and the severity of infection.</p><heading id="h0007"><u>The Compositions of the Invention</u></heading><p id="p0054" num="0054">In one aspect the compositions in form of solutions are osmotically balanced, and have minimal cytotoxicity.</p><p id="p0055" num="0055">In another aspect the compositions described herein have a therapeutic index of about 1000 to about 5,000, defined by the ratio of their 50% inhibitory concentration cytotoxicity index (IC<sub>50</sub>) at one hour against both L929 mouse lung epithelial cells and primary human fibroblasts to their Minimum Bactericidal Concentration against <i>Escherichia coli</i> ATCC 11229 at 37 °C for one hour.</p><p id="p0056" num="0056">Because the compositions of the present invention are nontoxic and have antibacterial properties, they are useful in any application in which antimicrobial properties are desirable. Such applications include, without limitation, treatment of wounds, bums, and canker sores; irrigation; cleaning of tissue sites (e.g., pre- and post-operative);<!-- EPO <DP n="18"> --> ophthalmic applications (<i>e.g.</i>, in contact lens cleaning solutions or for irrigation of the eye before, during, or post ophthalmic surgery); for dermatological applications, psoriasis; and numerous applications which are readily apparent to one skilled in the art. Application also includes the elimination or reduction of pathogens on surfaces including medical equipment, instruments, devices or food (without limiting to meat, fruits, vegetables) and food contact surfaces including the elimination or reduction bacterial biofilms. Unlike many anti-infective compositions used in similar applications, the compositions of the invention have minimal to no side effects.</p><p id="p0057" num="0057">The compositions of the invention which comprise N,N-dihaloamino acids or their derivatives may be incorporated into a variety of applications, including bandages or wound dressings. The compositions in form of physiologically balanced, acidic solutions may be used in combination with specially designed bandages in a wound treatment protocol. The specialized bandage may include an opening or "window" through which topical treatment materials such as the solution of the present invention may be applied.</p><p id="p0058" num="0058">Also disclosed herein is an article of manufacture comprising the composition of the invention packaged in a container. Surfaces of the container which are in contact with the composition of the invention are made of material which is not reactive with an oxidizing agent</p><p id="p0059" num="0059">The stability of a solution of N,N-dihaloamino acids and their derivatives permits the use of different forms of packaging that would be practical for use by patients. The solution may be packaged in several single-use 30 ml amber glass bottles with Teflon-lined screw caps and sealed with tape to ensure gas tightness. In one aspect, the same solution may be packaged in a 250 ml amber glass bottle or in a 250 ml non-reactive plastic bottle. However, up to 5 liter bottles may be used, because such larger volumes are practical for treatment of bums. Storage in these receptacles ensures long-term stability required for the uses of the compositions described herein in detail. Additionally, packaging may include a dual chamber system where component A is mixed with component B to form the final product, N,N-dihaloamino acid or its derivatives.<!-- EPO <DP n="19"> --></p><p id="p0060" num="0060">In one aspect, the solutions of the present invention may be stored in single-use containers. In another aspect, the solutions of the invention may be stored in single-use containers of various different sizes, configurations, and having different volumes as suitable for the desired applications as disclosed herein. In some applications, for example, the solution of the invention may be stored in single-use 30 mL, optionally disposable containers. In one aspect the present composition may be stored as powder together with pharmaceutically accepted excipients under inert gas at room temperature.</p><p id="p0061" num="0061">The compositions of the invention may include the following pharmaceutically acceptable carriers: sodium chloride to attain isotonicity, buffers, stabilizers, solvents, flavoring agents (in case of oral or nasopharyngeal administration and food industry), preserving agents, diluents, extenders and other auxiliary substances or excipients. Specific examples of pharmaceutically acceptable carriers and excipients that may be used are described in <nplcit id="ncit0018" npl-type="b"><text>Remington: The Science and Practice of Pharmacy, A. Gennaro, ed., 20th edition, Lippincott, Williams &amp; Wilkins, Philadelphia, PA</text></nplcit>; <nplcit id="ncit0019" npl-type="b"><text>Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992</text></nplcit>); <nplcit id="ncit0020" npl-type="b"><text>Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995</text></nplcit>), the disclosures of which are incorporated herein in their entirety. In general, water, a suitable oil, saline, lower alcohols, and glycols such as propylene glycol or polyethylene glycols may be suitable carriers for solutions. In one aspect solutions contain the active ingredient in a water soluble or aqueous medium soluble form, for example as a salt, together with suitable stabilizing agents, and if necessary, buffer substances. In addition, solutions may contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. Suitable pharmaceutical carriers are described in Remington: The Science and Practice of Pharmacy, the above-identified standard reference text in this field.</p><p id="p0062" num="0062">The compositions may further comprise other active ingredients, such as HOCl or other antibacterials as long as they do not interfere with the stability or function of the N,N-dihaloamino acids of the invention.</p><p id="p0063" num="0063">The amounts or concentrations of N,N-dihaloamino acid in the compositions of the invention may vary over broad ranges. For example, a composition may contain from 0.001 to 100% by weight of the composition of the N,N-dihaloamino acid. In case of 100%, the composition may be applied in the form of a powder without any carrier substance. A typical range of the composition will include 0.1 to 95% by weight of the<!-- EPO <DP n="20"> --> composition of the N,N-dihaloamino acid, for example, 0.1 to 50%, or 0.1 to 10%, for example, 0.5 to 5%. In solutions, usually a lower concentration of the N,N-dihaloamino acid will be applied. For example, a concentration of 1 to 2% may be appropriate in case of a rinse or spray.</p><p id="p0064" num="0064">In case of nasopharyngeal application a catheter for nasal application containing a 1% solution of the N,N-dihaloamino acid or its salt with a pH of 3.5 to 5 may be used for several weeks using about 10 to 15 ml of the solution for each treatment. After each treatment the rinsing solution will be suctioned off.</p><heading id="h0008"><u>Specific methods for using the compositions of the invention</u></heading><p id="p0065" num="0065">In one aspect, the compositions of the invention are administered or used topically.</p><p id="p0066" num="0066">The acidic solutions of the present invention may be used in treating a number of patients with deep wounds, which do not respond to usual medications and locally applied treatments. In one aspect, the present invention provides a method for the treatment of various medical conditions such as promoting wound healing, reduction of pathogens in open wounds, wound decontamination, ocular disinfection or decontamination, oral disinfection, antifungal therapy, ophthalmic applications, reduction of pathogens in pulmonary infections, reduction of pathogens in burns, lavage, reduction of infectious load in organs for transplantation, reduction of bacterial load in autologous or artificial tissue transplantation, oral disinfection antifungal therapy, treatment ofbiofilm for cystic fibrosis and related diseases, treatment of viral infections, treatment of skin diseases, and tissue repair and regeneration, which method comprises using the solution of the present invention by applying the solution to the site where treatment is required. Non-limiting examples of biofilm that may be treated using the solutions of the present invention include those cited in the review article entitled "<nplcit id="ncit0021" npl-type="s"><text>Is there a role for quorum signals in bacterial biofilms?" by S. Kjelleberg, and S. Molin</text></nplcit>, PMID: 12057677 (PubMed-indexed for MEDLINE).</p><p id="p0067" num="0067">The solutions of the invention may be effective in reducing bacterial load thus improving wound healing. The solutions could be well tolerated, improve the granulation of wound tissue, reduce the need for debridement compared to prior art solutions with patients reporting less pain during their treatment.<!-- EPO <DP n="21"> --></p><heading id="h0009"><u>Oral Care</u></heading><p id="p0068" num="0068">The acidic solution of the invention may be used to treat canker sores (mouth ulcers) or cold sores by rinsing the affected area. For example, the solution can be used by soaking the cold sore 3-4 times a day, each time with 2-3 applications, and putting the solution in contact with the sore for 20-30 seconds. The solution may also be used as a mouth rinse for dental and mouth hygiene and to control infection. In this instance, the solution may be used as a gargling solution to fight throat infection. The solution may be applied with the help of a cotton swab for more specific areas. The solution can be used once or several times a day according to a patient's needs and condition.</p><heading id="h0010"><u>Ophthalmic Care</u></heading><p id="p0069" num="0069">The physiologically-balanced, acidic solution of the invention may be used in place of a saline solution to remove a foreign body from, to rinse, or to irrigate the eyes. It can also be applied topically before or after surgery to disinfect an eye and surrounding tissues. The solution can be used once or several times a day according to a patient's needs and condition. The solution can be applied by dropping it directly into the eyes as necessary. It can also be applied by soaking a gauze and applying the saturated gauze to the eyes for 1 or several minutes. It can also be used to clean the eyes by gently wiping the eyes with saturated gauze. The solution can also be poured into a small eye washer, then the washer is inverted over the eye and the eyelid opened and closed several times.</p><p id="p0070" num="0070">The physiologically-balanced, acidic solution of the invention may be used for the treatment of ocular disinfection or decontamination. In addition, it may be used as a replacement for silver nitrate in the disinfection of the eyes of neonates.</p><p id="p0071" num="0071">The solutions of the present invention may be used for the cleaning eyes in adults and in pediatrics. For example, various viral infections, bacterial or fungal infections, or pathogenic agents may be effectively treated with the solution of the present invention. Non-limiting examples ofpathogenic agents that could be successfully treated with the solution of the present invention include chlamydia trachomatis, gonorrhea as well as other bacterial, fungal, and viral infections.</p><p id="p0072" num="0072">The reader will see that the solution of the invention has applications in the treatment of many different types of wounds, including, without limitation, diabetic ulcers, gangrene, venous ulcers, decubitus ulcers, pressure ulcers, wounds due to bites, acute trauma wounds, surgical wounds and burns. The composition of the invention is also useful as an irrigation solution, for example, during dental, periodontal, and<!-- EPO <DP n="22"> --> ophthalmic procedures. The composition of the invention can also be used for pre- and post-operative cleaning of tissue sites, and as a gargling solution for treatment of canker sores.</p><heading id="h0011"><u>Methods of Using a Solution for Skin Disinfection</u>:</heading><p id="p0073" num="0073">The solution of the present invention may also be used to treat skin that is infected. In a skin of a patient showing medical signs of infection, the solution of the present invention may be applied directly to the area of the skin that is infected. After at least one application of the solution onto the infected skin using standard methods of application known in the art, the disinfective properties of the solution may be noted.</p><heading id="h0012"><u>Reduction of Pathogens in Pulmonary Infections:</u></heading><p id="p0074" num="0074">The solution of the present invention may be used for the reduction of pathogens in pulmonary infections. For example, various viral or bacterial and fungal infections may be effectively treated with the solution of the present invention. Non-limited examples of infections that may be effectively treated using the solution of the present invention include anthrax spores present in the lungs, and the reduction of pneumonia causing bacteria in the lungs, including strep bacteria and the like.</p><p id="p0075" num="0075"><u>Methods of Using the Solutions of Invention in Gynecology:</u></p><p id="p0076" num="0076">The composition of the present invention may be used for the treatment of gynecological infections, such as urinary tract infections and the like. For example, various microorganisms, yeasts (<i>e.g., Monilia, Candida albicans,</i> etc), bacterial infections, HSV-2, HIV or other pathogenic agents may be effectively treated with the solution of the present invention. Optionally, the application of the solutions of the present invention can be used with other medications for the treatment of gynecological infections. For example, use as a lavage of birth canal in pregnant female patients with suspected venereal diseases, and potentially as bathing and cleansing solution on babies right after birth in the deliver rooms of hospitals or as disinfectant on catheters and shunt in dialysis room.</p><heading id="h0013"><u>Method of Use as a Treatment for Topical Infections</u></heading><p id="p0077" num="0077">The compounds of the current invention may be used to treat topical infections by incorporating them into creams, ointments or lotions for use in such conditions. Such creams, ointments or lotions might be used a broad variety of skin conditions and may incorporate penetration enhancers in order to deliver the antimicrobial activity of the compound to microbes present beneath the outer (epidermis) layers of the skin.<!-- EPO <DP n="23"> --></p><heading id="h0014"><u>Method of Use to Prevent Surgical Site Infections</u></heading><p id="p0078" num="0078">Isotonic solutions of the present invention may be used as an irrigant during surgery in order to prevent the development of surgical site infections, that frequently lead to prolonged hospitalizations and, occasionally, in death. The use of a solution of the present invention in place of saline could substantially reduce the risks of such infections especially in the case of gastric surgery and of prolonged operations, where the rate of infections may be as high as 10%.</p><heading id="h0015"><u>Method of Use for Disinfection of Medical Devices and Surgical Implements</u></heading><p id="p0079" num="0079">The solution of the present invention may be used for the reduction of pathogens on the surfaces of medical devices and surgical implements to prevent infection to the patient on whom the implements and devices are used, or in whom they are implanted.</p><p id="p0080" num="0080">The solution may also be used for the reduction or elimination of infections that occur at the entry ports of catheters and shunts that are particularly prone to such infections.</p><heading id="h0016"><u>Method of Use for Surface Disinfection</u></heading><p id="p0081" num="0081">The solution of the present invention may be applied directly or through delivery from a device that creates a mist (aerosolization) to the surfaces of a room, vehicle interior or other such largely confined space in order to reduce or eliminate infectious pathogens that may be suspected to be present. In such an application, it could be used to decontaminate operating theaters where infectious pathogens have been detected or rooms, vehicles and other surfaces where biological warfare agents have been dispersed.</p><heading id="h0017"><u>Method of Use for Improving Food Safety</u></heading><p id="p0082" num="0082">The solution of the present invention may be used for reducing pathogens on food (including, without limitation, meats, fruits and vegetables). The solution could be applied as a wash or mist to the food, or the food could be dipped in the solution. Taurine would be major residual product of such application and taurine is an essential nutrient that is considered to be safe in human food.</p><p id="p0083" num="0083">The solution of the present invention may also be applied to surfaces and implements used in the preparation of foods to prevent the transfer of pathogens from such surfaces and implements to the food.<!-- EPO <DP n="24"> --></p><heading id="h0018"><u>Method of Use as an Antimicrobial Preservative</u></heading><p id="p0084" num="0084">The compounds of the present invention may be used as a means of ensuring that microbes cannot survive in solutions intended for use in injection, infusion or for use in the eye by incorporation of an appropriate amount of such compound into the solution at the time of manufacture.</p><heading id="h0019"><u>Method of Use as an Antimicrobial</u></heading><p id="p0085" num="0085">The solution of the present invention may be used as a means of safely and rapidly disinfecting the hands of surgeons and nurses to reduce the risk of transporting infectious agents into an operating theatre. Additionally, solution of the present invention may be used to eliminate the infectious agent from the skin of patients (pre and post operative) in the area of a surgical incision.</p><heading id="h0020"><u>Method of Wound Care</u></heading><p id="p0086" num="0086">Patients suffering from long-lasting non-healing wounds should be treated with the acidic composition of the present invention on a daily basis, typically about once or twice a day.</p><p id="p0087" num="0087">The solution of the invention may be used as follows: a gauze material or gauze pad is presoaked with enough solution to saturate it and is then squeezed to remove excess solution. This removes species present in the gauze which would react with and reduce the effectiveness of the solution of the invention. The gauze is wetted after this procedure, but not soaked. Additional solution is then applied to completely wet the gauze, which is then immediately applied to the wound. In the alternative, the gauze may be applied to the wound and then additional solution is applied. Typically the wound site is packed with the solution soaked gauze, and optionally, a Vaseline gauze can be applied on top of the packed wound to keep it moist and free of contaminating germs. The wound site is then wrapped with wound dressings as is standard in the art. The solution may also be used to clean a wound by pouring it directly on the wound site to remove any necrotic tissue by a mechanical procedure, and also as a cleanser or irrigant.</p><p id="p0088" num="0088">The patient may also make use of a "wound care kit" provided by NovaCal which permits the patient to periodically pour the solution of the present invention onto the wound site without having to remove the dressing. This kit provides ease-of-use, portability and dramatically reduces exposure of the wound to / from re-infection. The wound care kit includes a package containing the solution of the invention and<!-- EPO <DP n="25"> --> bandaging material. Often the kit contains a package containing the solution of the invention and a specialized bandage for use in combination with the solution. The specialized bandage keeps the skin surrounding the wound dry while the wound is treated. Further, the bandage may be applied in a physician's office or at a hospital, with the patient continuing care at home; may be applied and used at home under the instructions of a physician; or for minor injuries, the wound care kit may be used as an "over the counter" treatment by the patient alone.</p><heading id="h0021"><u>Packaging for certain uses</u></heading><p id="p0089" num="0089">In another aspect of the invention, the solutions of the present invention may be packaged to contain the solution in individual, single use containers. The single-use containers may be used for example, for application in single change of dressing or equivalents thereof. The single use containers of the present invention may be used in conjunction with commonly used bandages. In another of the invention, a wound care kit may comprise single-use containers of the solutions of the present invention with the specialized bandages for various applications.</p><p id="p0090" num="0090">In another aspect of the invention, the solutions of the present invention may be produced in-situ by the use a dual-chamber apparatus or packaging as shown in the picture with or without a third mixing chamber.
<chemistry id="chem0002" num="0002"><img id="ib0005" file="imgb0005.tif" wi="57" he="82" img-content="chem" img-format="tif"/></chemistry></p><p id="p0091" num="0091">The Dual-Chamber may consist of two syringes or pouches. To make NNDCT solution with a concentration of 3.2 mM at pH 3.5, for example, chamber A is filled with 12.8 mM NaOCl solution, chamber B is filled with 3.3 mM taurine dissolved in acidified 1.8 % of saline solution. The acidity of the solution in chamber B is adjusted with 1 M<!-- EPO <DP n="26"> --> HCl so that when the solutions in two chambers are mixed either in a common delivery tube or in a mixing chamber C, the reaction will give desired NNDCT concentration and pH value. Since Taurine is stable in acidic solution, and NaOCl is stable at room temperature, the use of the on-site preparation method described above can avoid the stability problem of NNDCT solution.</p><heading id="h0022"><u>Example 1</u> (Reference-not part of the claimed invention)</heading><heading id="h0023"><u>Method of Preparation</u></heading><p id="p0092" num="0092">Reagents: All solutions were made with deionized, or Millipore water. NaOCl (6%) solution was purchased from VWR. Taurine was purchased from Sigma. NaCl and HCl are reagent-grade.</p><heading id="h0024"><u>Synthesis and Characterization of N,N-dichlorotaurine (NNDCT)</u></heading><p id="p0093" num="0093">In this study, NNDCT was prepared by dissolving taurine powder in HOCl solution (pH 3.5) at a HOCl/Taurine ratio of 2.<br/>
<br/>
        H<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>3</sub>H + 2 HOCl → Cl<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>3</sub><sup>-</sup> + H<sup>+</sup> + 2 H<sub>2</sub>O<br/>
<br/>
</p><p id="p0094" num="0094">To make 1 liter of 1.6 mM of NNDCT in 0.9% NaCl solution at pH 3.5, add 8.6 g of NaCl into a 1000-ml volumetric flask, then add 500 ml Millipore water into the flask to dissolve the salt. Add 2 ml of 1 M HCl into the NaCl solution, followed by adding 22 ml of 0.158 M NaOCl. Mix the solution. Then add 0.267 g of taurine into the flask and fill the volumetric flask up to the mark with Millipore water. Stir the solution for 5 minutes.</p><p id="p0095" num="0095">NNDCT has a maximum absorbance at 300 nm with a molar absorptivity of 370 M<sup>-1</sup>cm<sup>-1</sup>. When OCl<sup>-</sup> solution (pH 9.5) was added into the taurine solution, N-Chlorotaurine (NCT) (ClHN-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>3</sub><sup>-</sup>) was the only product formed.<br/>
<br/>
        H<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>3</sub>H + OCl<sup>-</sup> → ClHN-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>3</sub><sup>-</sup> + H<sub>2</sub>O<br/>
<br/>
NNDCT and NCT are spectrophotometrically distinguishable. NCT has a maximum absorbance at 252 nm. The yield of NNDCT was calculated from its absorbance at 300 nm. This preparation method gives a yield of 91 % of NNDCT. Iodometric titration gives a I<sub>2</sub>/NNDCT ratio of 2. This suggests that NNDCT retains the two oxidizing equivalents of HOCl. Both chlorine moieties in NNDCT are able to oxidize the I<sup>-</sup> to I<sub>2</sub>. NNDCT decomposes in solution, but it is more stable at low temperature. A stability study on NNDCT solution (pH 3.5) was performed at three temperatures, 4 °C, room temperature and 40 °C. The solution was sealed in ampoules. The stability of NNDCT<!-- EPO <DP n="27"> --> at three temperatures is in the following order: 4 °C &gt; room temperature &gt; 40 °C. In 4 weeks, 5.4 % of NNDCT is lost when stored in refrigerator (4 °C) ([NNDCT]<sub>initial</sub> = 1.47 mM).</p><p id="p0096" num="0096">N,N-dichlorotaurine is very soluble in water at a pH range from 1 to 10. N,N-dichlorotaurine can be identified and quantitatively determined by UV spectroscopy. N,N-dichlorotaurine has a maximum UV absorbance at 300 nm and a molar absorptivity of 370 M<sup>-1</sup>cm<sup>-1</sup>.</p><p id="p0097" num="0097">NNDCT is not volatile. A solution of 1.47 mM in 0.9% saline at pH 3.5 was filled in two glass bottles. One bottle was capped tightly and another was capped loosely. There was no difference in the concentration ofNNDCT in two bottles after 4 weeks at room temperature.</p><p id="p0098" num="0098">Isolation of the pure powder form of NNDCT and storage under inert atmosphere provides a more stable source for NNDCT. Additionally, reformulation of the solid matrix of NNDCT in a pill format assists in the stabilization ofNNDCT. This pill formulation has been selected to prevent decomposition while providing ease of use in the intended pharmaceutical application (contact lens disinfections, other application).</p><heading id="h0025"><u>Example 2</u> (Reference-not part of the claimed invention)</heading><heading id="h0026">Antimicrobial Activity</heading><heading id="h0027"><b>Bactericidal Activity:</b></heading><p id="p0099" num="0099">To determine the bactericidal activity, we used <i>Escherichia coli</i> (ATCC 11229). The bacterial culture was diluted in sterile saline to prepare inocula. Various test articles were transferred to individual tubes already containing 1.0 x 10<sup>5</sup> to 2.0 x 10<sup>5</sup> Colony Forming Units (CFU)/mL bacteria and mixed by gentle vortexing and then incubated at 37 °C for 1 or 24 hours. In an attempt to mimic as far as possible the conditions, which could be produced in vivo if the test articles were used as antiseptics, bacterial plating in a Petri dish was performed immediately after the designated exposure time without the addition of a neutralizer, and independently with addition of neutralizer (as control). Thus, 0.1 mL was removed after 1 or 24 hours exposure times and plated. Plates were incubated at 37 °C, and the numbers of bacteria were counted by direct colony count to numerate the surviving bacteria as CFU/mL. Positive growth controls were made with sterile 0.9% saline. All test articles were tested three times. The results were tabulated to show the comparison of antimicrobial effectiveness range of HOCl, OCl<sup>-</sup>, NNDCT and 0.9% saline at various pH levels. At pH 3.5 NNDCT showed an effective<!-- EPO <DP n="28"> --> antimicrobial concentration range between 0.0149 to 1.49 mM at 60 min, and an effective antimicrobial concentration range between 0.000149 to 1.49 mM at 24 hrs, whereas the effective antimicrobial concentration range for HOCl commenced at 0.016 at 60 min and at 0.0016 mM at 24 hrs. At pH 3.5 NNDCT was better or as effective against E. coli as HOCl.</p><p id="p0100" num="0100">In these studies for the first time we have demonstrated (in parallel) the bactericidal and cell toxicity profiles of N-Chloramines as compared to various test articles. Both N-Chlorotaurine (NCT) and N, N-Dichlorotaurine (NNDCT) were synthesized in 0.9% physiological concentration of NaCl with controlled pH according to procedures described above. These solutions were tested for their physicochemical properties before analyzing their biological activities. Diluted solutions of NCT and NNDCT are colorless and isotonic and display exceptionally rapid antimicrobial activity. Production of these oxidants appears to be pH-dependent. NCT is formed exclusively in alkaline pH, whereas NNDCT is formed in acidic pH.</p><p id="p0101" num="0101">Comparative antimicrobial assays using NNDCT in the solution of the present invention at pH 5.0 and 3.5 and NCT at pH 9.5 demonstrated a bacterial (E. coli) killing efficiency of about 300 fold greater for NNDCT at pH 3.5 over NNDCT at pH 5.0 and 1000 fold higher killing efficiency of NNDCT at pH 3.5 as compared to NCT at pH 9.5 within the 60 min exposure time at 37 °C (Table-1).
<tables id="tabl0001" num="0001"><table frame="all"><title><b>Table-1:</b> Product summary:</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="17mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="17mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="25mm"/><thead><row><entry align="center" valign="top"><b>Product</b></entry><entry align="center" valign="top"><b>Color</b></entry><entry align="center" valign="top"><b>pH</b></entry><entry align="center" valign="top"><b>Tonicity</b></entry><entry align="center" valign="top"><b>Physical Status</b></entry><entry align="center" valign="top"><b>MBC (µg/mL)</b></entry></row></thead><tbody><row><entry>NCT</entry><entry align="center">clear</entry><entry align="char" char="." charoff="13">9.5</entry><entry align="center">Isotonic</entry><entry align="center">solution</entry><entry align="center">142.5</entry></row><row><entry>NNDCT</entry><entry align="center">clear</entry><entry align="char" char="." charoff="13">5.0</entry><entry align="center">Isotonic</entry><entry align="center">solution</entry><entry align="center">38.0</entry></row><row><entry>NNDCT</entry><entry align="center">clear</entry><entry align="char" char="." charoff="13">3.5</entry><entry align="center">Isotonic</entry><entry align="center">solution</entry><entry align="center">0.136</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="17mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="17mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="25mm"/><tbody><row><entry namest="col1" nameend="col6" align="justify">MBC is the Minimum Bactericidal Concentration</entry></row></tbody></tgroup></table></tables></p><p id="p0102" num="0102">The antimicrobial activity and killing time not only were concentration dependent but also increased markedly by lowering the pH. NCT is less antimicrobial than NNDCT on an equal concentration basis by a factor of 1000 fold.</p><heading id="h0028"><u>Example 3</u> (Reference-not part of the claimed invention)</heading><heading id="h0029"><b>Cytotoxicity Assay:</b></heading><p id="p0103" num="0103">Cytotoxicity was assessed by a colorimetric assay system, initially described by Scudiero <i>et al.,</i> using 3'-(phenylamino-carbonyl)-3,4-tetrazolium-bis (4-methoxy-6-nitro)<!-- EPO <DP n="29"> --> benzene sulfonic acid hydrate (XTT), ProCheck™ cell viability assay (Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines described by<nplcit id="ncit0022" npl-type="s"><text> Scudiero DA, Shoemaker RAH, Paul KD, Monks A, Tierney S, Nofziger TH, Currens MJ, SeniffD, Boyd MR. Cancer Res. 1988 Sep 1;48(17):4827-33</text></nplcit>). Similar approaches for determining the cell viability are used by other investigators. Three cell types were used: mouse lung epithelial cells (L929), primary human skin fibroblast and primary human keratinocyte cells cultured in Dulbecco Modified Eagle's Medium and Keratinocyte defined medium with corresponding growth factors plus antibiotics. Cells were trypsinized and counted under the microscope and seeded at 1000-to-2000 cells per well of a flat-bottom 96-well plate. Cells were allowed to grow over-night at 37 °C. Next day, tissue culture media was removed and cells were rinsed with fresh media 1X and then left in 50 µL of tissue culture media. Test articles were prepared as 2-fold dilutions and 200 µL was added into each set of 4-wells (total volume per well = 250 µL). Cells were exposed to test articles for 60 min at room temperature. Immediately after the exposed time, test article from each well was removed and cells were fed with 250 µL of fresh media. Plates were incubated at 37 °C for 18-20 hours. The following day media was removed again and replaced with 100 µL/ well of fresh media containing 10/100 µL XTT-reagent. Cells were incubated under growth conditions (5% CO<sub>2</sub> at 37 °C humidified incubator), protected from light, until color development was achieved. Absorbance was read at 450 nm with reference wavelength at 750 nm using Molecular Device ThermoMax Plate reader, blanking the plate on the medium-only assay blank wells. Untreated cells receiving XTT reagents-only served as positive cell proliferation control.</p><p id="p0104" num="0104">When cell inhibitory concentration toxicity index (CCI<sub>50</sub>) was determined (measured as 50% of cells still alive), CCI<sub>50</sub> of NNDCT was at 7 mM and showed a substantially higher cell viability of Primary Human Skin Fibroblasts in the XTT Assay than for CI<sub>50</sub> of HOCl (IC<sub>50</sub> = 0.8 mM), betadine (IC<sub>50</sub> = 0.01 mM) or OCl<sup>-</sup> (IC<sub>50</sub> = 0.66 mM). Similar results were attained in the XTT Assay performed on mouse lung epithelial cells (L929) where more than 90% viability for NNDCT was observed at a concentration of 7 mM versus substantially less than 50% viability for OCl<sup>-</sup> at concentrations of 0.6 mM and betadine at concentrations of 0.02 mM.<!-- EPO <DP n="30"> --></p><heading id="h0030"><u>Cytotoxicity and Therapeutic Index</u></heading><p id="p0105" num="0105">NNDCT has been subjected to rigorous in vitro safety testing using United States Pharmacopoeia's standard cell assay (mouse lung epithelial cells, L929), as well as primary human skin cells. We discovered that NNDCT has a very low cell toxicity index in both cell types: Primary human fibroblast and L929 cells as compared to other antiseptic test articles: HOCl and Povidone-Iodine (see below). Unlike Povidone Iodine where cell toxicity was a major concern, NNDCT demonstrated to be cell compatible with a much safer toxicity profile. In fact, the therapeutic index (TI), which is defined as the ratio of a concentration tolerated by the assayed cells (in vitro cytotoxicity or ICI<sub>50</sub>) over the Minimum Bactericidal Concentration (MBC) for NNDCT was about 5,000 as compared to about 300 and 7 for HOCl and Povidone-Iodine, respectively (Table 2).
<tables id="tabl0002" num="0002"><table frame="all"><title>Table-2 Summary of Minimum Bactericidal Concentration (MBC) and Therapeutic Index data</title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="29mm"/><colspec colnum="2" colname="col2" colwidth="25mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><colspec colnum="5" colname="col5" colwidth="25mm"/><thead><row><entry align="center" valign="top"><b>Product</b></entry><entry align="center" valign="top"><b>pH</b></entry><entry align="center" valign="top"><b>MBC<sup>a</sup> (µg/mL)</b></entry><entry align="center" valign="top"><b>ICI<sub>50</sub> (µg/mL)</b></entry><entry align="center" valign="top"><b>T.I<sup>b</sup>. on HF<sup>c</sup></b></entry></row></thead><tbody><row><entry>NNDCT</entry><entry align="char" char="." charoff="8">3.5</entry><entry align="char" char="." charoff="7">0.29</entry><entry align="center">1442</entry><entry align="center">4972</entry></row><row><entry>HOCl</entry><entry align="char" char="." charoff="8">3.5</entry><entry align="char" char="." charoff="7">0.16</entry><entry align="center">47</entry><entry align="center">297</entry></row><row><entry>Povidone-Iodine</entry><entry align="char" char="." charoff="8">4.2</entry><entry align="char" char="." charoff="7">0.38</entry><entry align="center">2.5</entry><entry align="center">7</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="29mm"/><colspec colnum="2" colname="col2" colwidth="25mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><colspec colnum="5" colname="col5" colwidth="25mm"/><tbody><row><entry namest="col1" nameend="col5" align="justify"><sup>a</sup> Minimum Bactericidal Concentration (MBC)<br/>
<sup>b</sup>Therapeutic Index and <sup>c</sup>Primary human skin fibroblast cells.</entry></row></tbody></tgroup></table></tables></p><p id="p0106" num="0106">Application ofNNDCT as safer topical disinfectant particularly in ophthalmic, chronic non-healing wounds and burn patients could be a great advantage, because use of other disinfectants with major toxic side effects is highly discouraged by healthcare authorities. Since food safety is also a major health issue, the application of NNDCT as a broad disinfectant can be extended to food industry.</p><heading id="h0031"><u>Example 4</u></heading><p id="p0107" num="0107">As an example, the procedure for the preparation of N,N-dichloro-2-amino-2-methyl propanesulfonic acid is described as follows:</p><heading id="h0032">Step 1 Synthesis of 2-amino-2-methyl propanesulfonic acid (Braghiroli, D.; Bella, M. D. Tetrahedron Letters, 1996, <i>37</i>, 7319-7322).</heading><p id="p0108" num="0108">2-amino-2-methylpropanesulfonic acid is prepared by reduction of 2-hydroxyisobutyronitrile (acetone cyanohydrin) to 1-amino-2-methyl-2-propanol, followed by protection with<!-- EPO <DP n="31"> --> (Boc)<sub>2</sub>O. After mesylation and removal of the protecting group, the hydrochloride obtained was allowed to react with sodium sulfite to give 1,1-dimethylethanesulphonic acid.</p><heading id="h0033">Step 2 Chlorination of 2-amino-2-methylpropanesulfonic acid.</heading><p id="p0109" num="0109">To make 1 liter of 1.6 mM of N,N-Dichloro (NNDC-DMESA) in 0.9% NaCl solution at pH 3.5, add 8.6 g of NaCl into a 1000-ml volumetric flask, then add 500 ml Millipore water into the flask to dissolve the salt. Add 2 ml of 1 M HCl into the NaCl solution, followed by adding 22 ml of 0.158 M NaOCl. Mix the solution. Then add 0.355 g of 2-amino-2-methylpropanesulfonic acid into the flask and fill the volumetric flask up to the mark with Millipore water. Stir the solution until the reaction is completed as indicated for example by UV or NMR. We have prepared N,N-chlorinated ornithine, N,N-dichloro homotaurine and N,N-dichloro alanine. All these dichloro compounds have very similar UV spectra (λ<sub>max</sub>=∼ 300 nm) and molar absorptivities.</p><heading id="h0034"><b>Procedure for preparing the dichloro-amino acid compounds</b></heading><p id="p0110" num="0110">Into an acidic HOCl solution, a stoichiometric amount of amino acid or their salt (powder) is added (the molar ratio of HOCl : amino acid = 2:1). Then the mixture solution is stirred for about 15 minutes. The pH of the resulting solution is lower than the pH of the starting HOCl solution. The product is identified and the completion of the reaction is followed by an UV-vis spectrophotometer. The pH of the solution is adjusted with hydrochloric acid or sodium hydroxide solution to the desired pH value. The concentration of the solution is determined on UV spectrophotometer by using the corresponding molar absorptivity at the λ<sub>max</sub>. A more detailed procedure is described in the following example.</p><heading id="h0035">Example: Preparing 1 liter of 0.05 M of Dichloro Homotaurine solution.</heading><p id="p0111" num="0111"><ul><li>Step 1. Prepare 1 liter of 0.1 M HOCl solution with a pH &lt; 5.</li><li>Step 2. Add 8.06 g of sodium homotaurine (sodium 3-amino-1-propansulfonic, MW = 161.13) into the HOCl solution in step 1. Stir the solution for about 15 minutes.</li><li>Step 3. Take an aliquot of solution in step 2 and make 100-fold dilution. Take the UV spectrum of the diluted solution to identify the product, which has λ<sub>max</sub> at 303 nm (see the attached table).</li><li>Step 4<br/>
Adjust the pH of the solution resulted in step 2 to the desired pH with NaOH or HCl.<!-- EPO <DP n="32"> --></li><li>Step 5<br/>
Repeat the procedure in step 3 to measure the concentration of the dichloro Homotaurine (the molar absorptivity is 329.0 M<sup>-1</sup>cm<sup>-1-</sup>, see the attached table).</li></ul><tables id="tabl0003" num="0003"><table frame="topbot"><title><b>Table</b></title><tgroup cols="3" colsep="0"><colspec colnum="1" colname="col1" colwidth="48mm"/><colspec colnum="2" colname="col2" colwidth="34mm"/><colspec colnum="3" colname="col3" colwidth="38mm"/><thead><row><entry namest="col1" nameend="col3" align="center" valign="top">Molar Absorptivities of N,N-Dichloro- and N,N-dibromo- Amino Acid Compounds</entry></row><row><entry align="center" valign="top">Compounds</entry><entry align="center" valign="top">λ<sub>max</sub> (nm)</entry><entry align="center" valign="top">ε (M<sup>-1</sup>cm<sup>-1</sup>)</entry></row><row><entry align="center" valign="top">N,N-dichloro taurine</entry><entry align="center" valign="top">302</entry><entry align="center" valign="top">332.9<sup>a</sup></entry></row></thead><tbody><row><entry align="center">N,N-dichloro homotaurine</entry><entry align="center">303</entry><entry align="center">329.0<sup>c</sup></entry></row><row><entry align="center">N,N-dichloro β-alanine</entry><entry align="center">301</entry><entry align="center">327.6<sup>c</sup></entry></row><row><entry align="center">N,N,N',N'-tetrachloro omithine</entry><entry align="center">300<sup>c,d</sup></entry><entry align="center">241<sup>c,d</sup></entry></row><row><entry align="center">N,N-dibromo taurine</entry><entry align="center">241</entry><entry align="center">2713<sup>b</sup>, 2708<sup>c</sup></entry></row></tbody></tgroup><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="48mm"/><colspec colnum="2" colname="col2" colwidth="34mm"/><colspec colnum="3" colname="col3" colwidth="38mm"/><tbody><row><entry namest="col1" nameend="col3" align="justify"><sup>a</sup><nplcit id="ncit0023" npl-type="s"><text>Gottardi, W.; Nagl, M. Arch. Pharm. Pharm. Med. Chem. 2002, 9, 411-421</text></nplcit>.<br/><sup>b</sup><nplcit id="ncit0024" npl-type="s"><text> Thomas, E.; Bozeman, P.; Jefferson, M.; King, C. J. Bio. Chem. 1995, 7, 2906-2913</text></nplcit>.<br/><sup>c</sup> determined in this study.<br/>
<sup>d</sup> based on a 4:1 molar ratio of chlorinating agent to ornithine.</entry></row></tbody></tgroup></table></tables></p><heading id="h0036"><u>Example 5</u> (Reference-not part of the claimed invention)</heading><p id="p0112" num="0112">The results of our discovery provide support for antimicrobial activity ofNNDCT in 0.9% saline at pH 3.5. These antimicrobial activities were determined to be considerable in a <i>µ</i>M range and increased significantly by increasing the concentration and or exposure time. In contrast, cell toxicity was seen at a 1000-fold higher range in the mM range. We showed that NNDCT treated cells were able to tolerated the treatment and be able to go through normal cell proliferation cycles as compared to untreated control cells in our XTT assay.<!-- EPO <DP n="33"> --></p><heading id="h0037"><u>Example 6</u> (Reference-not part of the claimed invention)</heading><p id="p0113" num="0113">NNDCT solutions with a concentration of 1.49 mM at pH 3.0, 3.5, 4.0, and 5.0 were prepared. The spectra and the concentrations of the solutions were measured on the UV-vis spectrometer. The results showed that the spectrum and the concentration of NNDCT solution did not change in the pH range from 3.0 to 5.0.</p><heading id="h0038">Preparation</heading><p id="p0114" num="0114">Add 8.8 g NaCl, 2 ml of 1.0 M HCl, and 0.278 g of taurine into a 1000-ml volumetric flask, followed by adding about 800 ml of deionized water into the flask. Shake the flask to dissolve NaCl and taurine powders. Then add 22 ml of 0.15M of the NaOCl solution into the flask. Fill the flask up to the mark with deionized water. Stir the solution with a magnetic stirring bar for 5 minutes. The concentration and the pH of the resulting solution were measured on a UV-vis spectrometer and a freshly calibrated Beckman pH meter. This solution has a concentration of 1.49 mM and a pH value of 3.85.<br/>
100 ml ofNNDCT solution above (pH = 3.85) was pipetted into a 250-ml beaker, 0.09 ml of 1.0 M HCl solution was added to this solution and stir. The final pH of this solution is 3.0.<br/>
100 ml ofNNDCT solution with pH 3.85 solution was pipetted into a 250-ml beaker, 0.003 ml of 5.0 M NaOH solution was added to this solution and stir. The final pH of this solution is 4.85.</p><p id="p0115" num="0115">Solutions with varying pH values were prepared in a similar manner within the pH range of 3 to 5. All solutions show stability if properly stored as shown by their UV spectra.</p></description><claims mxw-id="PCLM56979854" lang="DE" load-source="patent-office"><!-- EPO <DP n="37"> --><claim id="c-de-01-0001" num="0001"><claim-text>Zusammensetzung mit bakterizidaler, antibakterieller, anti-infektiöser, antimikrobieller, desinfizierender, antifungaler, sporenabtötender und antiviraler Aktivität, umfassend eine N,N-Dihalo-aminosäure, die ausgewählt ist aus der Gruppe bestehend aus N,N-Dichloro-2,2-dimethyltaurin, N,N-Dichloro-1,1,2,2-tetramethyltaurin, N,N-Dibromo-2,2-dimethyltaurin, N,N-Dibromo-1,1,2,2-tetramethyltaurin, N,N-Dichloro-3,3-dimethylhomotaurin, oder ein Derivat hiervon; wobei das Derivat ausgewählt ist aus der Gruppe bestehend aus pharmazeutisch akzeptablen Salzen und Estern mit C<sub>1</sub>-C<sub>6</sub>-Alkanolen.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Zusammensetzung gemäß Anspruch 1, worin die Zusammensetzung einen pharmazeutisch akzeptablen Träger umfasst.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Zusammensetzung gemäß Anspruch 1 mit einem pH-Wert im Bereich zwischen 2 bis 7, oder 3,0 bis 6,0, oder 3,0 bis 5,0, oder 3,5.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Zusammensetzung gemäß Anspruch 1, wobei die Zusammensetzung isotonisch und physiologisch ausgeglichen ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Zusammensetzung gemäß Anspruch 1, worin die N,N-Dihaloaminosäure ausgewählt ist aus der Gruppe bestehend aus N,N-Dichloro-2,2-dimethyltaurin, N,N-Dichloro-1,1,2,2-tetramethyltaurin, N,N-Dibromo-2,2-dimethyltaurin, N,N-Dibromo-1,1,2,2-tetramethyltaurin und N,N-Dichloro-3,3-dimethylhomotaurin.<!-- EPO <DP n="38"> --></claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>N,N-Dihaloaminosäure, ausgewählt aus der Gruppe bestehend aus N,N-Dichloro-2,2-dimethyltaurin, N,N-Dichloro-1,1,2,2-tetramethyltaurin, N,N-Dibromo-2,2-dimethyltaurin, N,N-Dibromo-1,1,2,2-tetramethyltaurin, N,N-Dichloro-3,3-dimethylhomotaurin, oder ein Derivat hiervon, worin das Derivat ausgewählt ist aus der Gruppe bestehend aus pharmazeutisch akzeptablen Salzen und Estern mit C<sub>1</sub>-C<sub>6</sub>-Alkanolen.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>N,N-Dihaloaminosäure gemäß Anspruch 6, die N,N-Dichloro-2,2-dimethyltaurin ist; oder ein pharmazeutisch akzeptables Salz hiervon.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Zusammensetzung, umfassend eine N,N-Dihaloaminosäure gemäß Anspruch 6 oder ein Derivat hiervon, wobei das Derivat ausgewählt ist aus der Gruppe bestehend aus pharmazeutisch akzeptablen Salzen und Estern mit C<sub>1</sub>-C<sub>6</sub>-Alkanolen, zur Verwendung in der Medizin.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verwendung einer N,N-Dihaloaminosäure gemäß irgendeinem der Ansprüche 6 bis 8 in der Herstellung einer Zusammensetzung mit bakterizidaler, antibakterieller, anti-infektiöser, antimikrobieller, sporenabtötender, desinfizierender, antifungaler und antiviraler Aktivität oder in der Herstellung einer Medikamentzusammensetzung für eine bakterizidale, antibakterielle, antiinfektiöse, sporenabtötende, desinfizierende, antifungale und antivirale Verwendung.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verfahren zur Desinfizierung durch Kontrollieren oder Vermeiden des Wachstums von Bakterien, Mikroben, Sporen, Pilzen oder Viren, wobei das Verfahren die Anwendung einer effektiven Menge einer Zusammensetzung gemäß Anspruch 1 auf eine Fläche, einen Raum oder ein Material umfasst, welches die Kontrolle oder die Vermeidung des Wachstums oder des Wucherns erfordert, vorausgesetzt, dass das Verfahren nicht als ein Verfahren zur Behandlung<!-- EPO <DP n="39"> --> des menschlichen oder tierischen Körpers durch Therapie verwendet wird.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verfahren gemäß Anspruch 10, worin der pH-Wert der Zusammensetzung zwischen 2 bis 7, 3,0 bis 6,8, oder 3,0 bis 6,0, oder 3,0 bis 5,0, oder 3,5 beträgt.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verfahren gemäß Anspruch 10, worin die N,N-Dihaloaminosäure oder das Derivat hiervon in situ hergestellt wird.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verfahren gemäß Anspruch 10, worin das zu behandelnde Material aus Lebensmitteln, Tiernahrung, chirurgischen Instrumenten, chirurgischer Ausrüstung, medizinischen Vorrichtungen und Aufrüstungsgegenständen, die für solche Zwecke verwendet werden, ausgewählt ist.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Zusammensetzung gemäß Anspruch 8 mit einer Konzentration der N,N-Dihaloaminosäure oder dessen Derivats zwischen 0,1 und 100 oder 0,3 bis 50 mM und einem pH-Wert im Bereich zwischen 2 bis 7, 3 bis 4,8, 3,0 bis 4,5 oder 3,5 bis 4,5 oder 3,5.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Zusammensetzung gemäß Anspruch 8 in stabilisierter Form, wobei die Zusammensetzung eine Konzentration der N,N-Dihaloaminosäure oder dessen Derivats zwischen 0,1 und 100 oder 0,1 bis 50 mM und einen pH-Wert im Bereich zwischen 2 bis 7,3 bis 6,3 bis 4,8, 3 bis 4,5 oder 3,5 bis 4,5 oder von 3,5 aufweist.</claim-text></claim></claims><claims mxw-id="PCLM56979855" lang="EN" load-source="patent-office"><!-- EPO <DP n="34"> --><claim id="c-en-01-0001" num="0001"><claim-text>A composition with bactericidal, antibacterial, anti-infective, antimicrobial, disinfectant, antifungal, sporicidal and antiviral activity comprising an N,N-dihalo-amino acid selected from the group consisting of N,N-dichloro-2,2-dimethyltaurine, N,N-dichloro-1,1,2,2-tetramethyltaurine, N,N-dibromo-2,2-dimethyltaurine, N,N-dibromo- 1,1,2,2-tetramethyltaurine, N,N-dichloro-3,3-dimethylhomotaurine, or a derivative thereof; said derivative being selected from the group consisting of pharmaceutically acceptable salts and esters with C<sub>1</sub>-C<sub>6</sub> alkanols.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The composition of claim 1 wherein the composition comprises a pharmaceutically acceptable carrier.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The composition of claim 1 having a pH range between 2 to 7, or 3.0 to 6.0, or 3.0 to 5.0, or 3.5.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The composition of claim 1, said composition being isotonic and physiologically balanced.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The composition of claim 1 wherein the N,N-dihaloamino acid is selected from the group consisting of N,N-dichloro-2,2-dimethyltaurine, N,N-dichloro-1,1,2,2-tetramethyltaurine, N,N-dibromo-2,2-dimethyltaurine, N,N-dibromo-1,1,2,2-tetramethyltaurine, and N,N-dichloro-3,3-dimethylhomotaurine.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>An N,N-dihaloamino acid selected from the group consisting of N,N-dichloro-2,2-dimethyltaurine, N,N-dichloro-1,1,2,2-tetramethyltaurine, N,N-dibromo-2,2-dimethyltaurine, N,N-dibromo-1,1,2,2-tetramethyltaurine, N,N-dichloro-3,3-dimethylhomotaurine, or a derivative<!-- EPO <DP n="35"> --> thereof, wherein the derivative is selected from the group consisting of pharmaceutically acceptable salts and esters with-C<sub>1</sub>-C<sub>6</sub> alkanols.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The N,N-dihaloamino acid of Claim 6 that is N,N-dichloro-2,2-dimethyltaurine; or a pharmaceutically acceptable salt thereof.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A composition comprising an N,N-dihalo amino acid of Claim 6 or a derivative thereof, said derivative being selected from the group consisting of pharmaceutically acceptable salts and esters with-C<sub>1</sub>-C<sub>6</sub> alkanols, for use in medicine.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The use of an N,N-dihalo-amino acid of any one of Claims 6 to 8 in the preparation of a bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral activity composition or in the preparation of a medicament composition for bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral use.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A method for disinfection by controlling or preventing the growth of bacteria, microbes, spores, fungi or viruses, said method comprising the application of an effective amount of a composition according to Claim 1 to an area, space or material requiring said control or prevention of growth or proliferation with the proviso that the method is not used as a method for treatment of the human or animal body by therapy.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The method of Claim 10, wherein the pH of the composition is between 2 to 7, 3.0 to 6.8, or 3.0 to 6.0, or 3.0 to 5.0, or 3.5.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The method of Claim 10, wherein said N,N-dihalo-amino acid or derivative thereof is prepared in situ.<!-- EPO <DP n="36"> --></claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The method of Claim 10, wherein the material to be treated is selected from food, animal feed, surgical instruments, surgical equipment, medical devices and equipment used for such purposes.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The composition of Claim 8 having a concentration of the N,N-dihaloamino acid or its derivative between 0.1 and 100 or 0.3 to 50 mM and a pH range between 2 to 7, 3 to 4.8, 3.0 to 4.5, or 3.5 to 4.5, or at 3.5.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The composition of Claim 8 in stabilized form, said composition having a concentration of the N,N-dihaloamino acid or its derivative between 0.1 and 100 or 0.1 to 50 mM and a pH range between 2 to 7, 3 to 6, 3 to 4.8, 3 to 4.5, or 3.5 to 4.5, or at 3.5.</claim-text></claim></claims><claims mxw-id="PCLM56979856" lang="FR" load-source="patent-office"><!-- EPO <DP n="40"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Composition avec une activité bactéricide, antibactérienne, anti-infectieuse, antimicrobienne, désinfectante, antifongique, sporicide et antivirale comprenant un acide N,N-dihalogéno-aminé choisi dans le groupe constitué par la N,N-dichloro-2,2-diméthyltaurine, la N,N-dichloro-1,1,2,2-tétraméthyltaurine, la N,N-dibromo-2,2-diméthyltaurine, la N,N-dibromo-1,1,2,2-tétraméthyltaurine, la N,N-dichloro-3,3-diméthylhomotaurine, ou un dérivé de celles-ci ; ledit dérivé étant choisi dans le groupe constitué par les sels pharmaceutiquement acceptables et les esters avec des alcanols en C<sub>1</sub>-C<sub>6</sub>.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composition selon la revendication 1, dans laquelle la composition comprend un support pharmaceutiquement acceptable.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composition selon la revendication 1 ayant une gamme de pH entre 2 à 7, ou 3,0 à 6,0, ou 3,0 à 5,0, ou 3,5.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composition selon la revendication 1, ladite composition étant isotonique et équilibrée physiologiquement.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Composition selon la revendication 1, dans laquelle l'acide N,N-dihalogénoaminé est choisi dans le groupe constitué par la N,N-dichloro-2,2-diméthyltaurine, la N,N-dichloro-1,1,2,2-tétraméthyltaurine, la N,N-dibromo-2,2-diméthyltaurine, la N,N-dibromo-1,1,2,2-tétraméthyltaurine, et la N,N-dichloro-3,3-diméthylhomotaurine.<!-- EPO <DP n="41"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Acide N,N-dihalogénoaminé choisi dans le groupe constitué par la N,N-dichloro-2,2-diméthyltaurine, la N,N-dichloro-1,1,2,2-tétraméthyltaurine, la N,N-dibromo-2,2-diméthyltaurine, la N,N-dibromo-1,1,2,2-tétraméthyltaurine, la N,N-dichloro-3,3-diméthylhomotaurine, ou un dérivé de celles-ci, dans lequel le dérivé est choisi dans le groupe constitué par les sels pharmaceutiquement acceptables et les esters avec des alcanols en C<sub>1</sub>-C<sub>6</sub>.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Acide N,N-dihalogénoaminé selon la revendication 6 qui est la N,N-dichloro-2,2-diméthyltaurine ; ou un sel pharmaceutiquement acceptable de celle-ci.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Composition comprenant un acide N,N-dihalogénoaminé selon la revendication 6 ou un dérivé de celui-ci, ledit dérivé étant choisi dans le groupe constitué par les sels pharmaceutiquement acceptables et les esters avec des alcanols en C<sub>1</sub>-C<sub>6</sub>, pour une utilisation en médecine.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Utilisation d'un acide N,N-dihalogéno-aminé selon l'une quelconque des revendications 6 à 8 dans la préparation d'une composition à activité bactéricide, antibactérienne, anti-infectieuse, antimicrobienne, sporicide, désinfectante, antifongique et antivirale ou dans la préparation d'une composition médicamenteuse pour une utilisation bactéricide, antibactérienne, anti-infectieuse, antimicrobienne, sporicide, désinfectante, antifongique et antivirale.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Procédé pour une désinfection par le contrôle ou la prévention de la croissance des bactéries, microbes, spores, champignons ou virus, ledit procédé comprenant l'application d'une quantité efficace d'une composition<!-- EPO <DP n="42"> --> selon la revendication 1 à une zone, un espace ou un matériel nécessitant ledit contrôle ou ladite prévention de la croissance ou la prolifération à condition que le procédé ne soit pas utilisé comme procédé pour le traitement du corps humain ou animal par thérapie.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Procédé selon la revendication 10, dans lequel le pH de la composition est entre 2 à 7, 3,0 à 6,8, ou 3,0 à 6,0, ou 3,0 à 5,0, ou 3,5.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Procédé selon la revendication 10, dans lequel ledit acide N,N-dihalogéno-aminé ou dérivé de celui-ci est préparé in situ.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Procédé selon la revendication 10, dans lequel le matériau à traiter est choisi parmi un aliment, un aliment pour animaux, des instruments chirurgicaux, un équipement chirurgical, des dispositifs médicaux et un équipement utilisé à de telles fins.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Composition selon la revendication 8 ayant une concentration de l'acide N,N-dihalogénoaminé ou de son dérivé comprise entre 0,1 et 100 ou 0,3 à 50 mM et une gamme de pH comprise entre 2 à 7, 3 à 4,8, 3,0 à 4,5, ou 3,5 à 4,5, ou à 3,5.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Composition selon la revendication 8 sous une forme stabilisée, ladite composition ayant une concentration de l'acide N,N-dihalogénoaminé ou de son dérivé comprise entre 0,1 et 100 ou 0,1 à 50 mM et une gamme de pH comprise entre 2 à 7, 3 à 6, 3 à 4,8, 3 à 4,5, ou 3,5 à 4,5 ou à 3,5.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
